Should I buy or sell FibroGen stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares. View FGEN analyst ratings or view top-rated stocks .

What is FibroGen's stock price target for 2024?

4 Wall Street research analysts have issued 1-year price targets for FibroGen's shares. Their FGEN share price targets range from $2.00 to $32.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,353.0% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts .

How have FGEN shares performed in 2024?

FibroGen's stock was trading at $0.8863 at the beginning of 2024. Since then, FGEN stock has increased by 32.0% and is now trading at $1.17. View the best growth stocks for 2024 here .

Are investors shorting FibroGen?

FibroGen saw a drop in short interest in March. As of March 31st, there was short interest totaling 5,190,000 shares, a drop of 6.1% from the March 15th total of 5,530,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is currently 1.9 days. Currently, 5.7% of the shares of the company are sold short. View FibroGen's Short Interest .

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our FGEN earnings forecast .

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.15. The biopharmaceutical company had revenue of $27.14 million for the quarter, compared to analyst estimates of $40 million.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Athabasca Oil (ATH) , Aegean Marine Petroleum Network (ANW) , NIC (EGOV) , Gran Tierra Energy (GTE) , Allergan (AGN) and ALJ Regional (ALJJ) .

When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FGEN

FibroGen (FGEN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free FGEN Stock Alerts

$1.17

-0.10 (-7.87%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.14
▼
$1.29
50-Day Range: $1.27
▼
$2.73
52-Week Range: $0.33
▼
$20.73

Volume: 1.28 million shs
Average Volume: 2.52 million shs
Market Capitalization: $115.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get FibroGen alerts:

FibroGen MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.75 Rating Score
Upside/Downside: 1,353.0% Upside
$17.00 Price Target
Short Interest: Healthy
5.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.84
Upright™ Environmental Score
News Sentiment: 1.11
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$95,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.09) to ($0.06) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

106th out of 919 stocks

Pharmaceutical Preparations Industry

30th out of 410 stocks

2.9

Analyst's Opinion

Consensus Rating
FibroGen has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
FibroGen has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.65% of the float of FibroGen has been sold short.
Short Interest Ratio / Days to Cover
FibroGen has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in FibroGen has recently decreased by 6.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
FibroGen does not currently pay a dividend.
Dividend Growth
FibroGen does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
FibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for FibroGen is -0.84.

3.4

News and Social Media Coverage

News Sentiment
FibroGen has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for FibroGen this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
11 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.39% of the stock of FibroGen is held by insiders.
Percentage Held by Institutions
72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for FibroGen are expected to grow in the coming year, from ($1.09) to ($0.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of FibroGen is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of FibroGen is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About FibroGen Stock (NASDAQ:FGEN)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FGEN Stock News Headlines

April 18, 2024 | americanbankingnews.com

FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.1% in March

April 17, 2024 | msn.com

FibroGen (FGEN) Price Target Increased by 40.00% to 1.79

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 3, 2024 | markets.businessinsider.com

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

April 3, 2024 | msn.com

FibroGen falls after early-stage data for prostate cancer drug

April 3, 2024 | markets.businessinsider.com

FibroGen (FGEN) Gets a Sell from Goldman Sachs

April 2, 2024 | globenewswire.com

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

March 26, 2024 | globenewswire.com

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 20, 2024 | investorplace.com

3 Nightmare Nasdaq Stocks Not Worth Holding Another Day

March 11, 2024 | finanznachrichten.de

FibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

March 11, 2024 | markets.businessinsider.com

FibroGen Appoints Deyaa Adib As CMO

March 11, 2024 | globenewswire.com

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

February 29, 2024 | finance.yahoo.com

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results

February 29, 2024 | finance.yahoo.com

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

FibroGen Full Year 2023 Earnings: Misses Expectations

February 27, 2024 | finanznachrichten.de

FibroGen, Inc.: FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | finance.yahoo.com

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023

February 26, 2024 | reuters.com

FibroGen regains rights to anemia drug from AstraZeneca

February 26, 2024 | globenewswire.com

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | globenewswire.com

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

February 25, 2024 | markets.businessinsider.com

Here's what Wall Street expects from FibroGen's earnings report

February 24, 2024 | finance.yahoo.com

FGEN Jan 2026 1.000 call

February 23, 2024 | benzinga.com

FibroGen's Earnings Outlook

February 21, 2024 | benzinga.com

FibroGen Stock (NASDAQ:FGEN) Insider Trades

February 21, 2024 | morningstar.com

First Gen Corp FGEN

February 20, 2024 | finance.yahoo.com

FGEN Jan 2025 3.500 call

See More Headlines

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FGEN
CUSIP: N/A
CIK: 921299
Web: www.fibrogen.com
Phone: (415) 978-1200
Fax: 415-978-1902
Employees: 486
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $32.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +1,359.2%
Consensus Rating: Reduce
Rating Score (0-4): 1.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-284,230,000.00
Net Margins: -192.37%
Pretax Margin: -194.15%
Return on Equity: N/A
Return on Assets: -51.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.52
Quick Ratio: 1.33

Sales & Book Value

Annual Sales: $147.75 million
Price / Sales: 0.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.87) per share
Price / Book: -0.62

Miscellaneous

Outstanding Shares: 98,770,000
Free Float: 96,410,000
Market Cap: $115.07 million
Optionable: Optionable
Beta: 0.70

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Thane Wettig (Age 59)
CEO & Director
Comp: $807.35k
Mr. Juan Graham (Age 47)
Senior VP & CFO
Comp: $991.76k
Ms. Christine L. Chung (Age 56)
Senior Vice President of China Operations
Comp: $1.27M
Dr. Barry A. Berkowitz Ph.D.
Founder
Dr. John J. Hunter Ph.D. (Age 61)
Chief Scientific Officer
David DeLucia
Vice President of Corporate FP&A and Investor Relations
Mr. Michael D. Lowenstein J.D.
Ph.D., Chief Legal Officer
Ms. Tricia Stewart
Chief People Officer
Mr. Kirk A. Christoffersen MBA (Age 55)
Chief Business Officer
Dr. Rahul Rajan Kaushik Ph.D.
Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings or view top-rated stocks.
What is FibroGen's stock price target for 2024?: 4 Wall Street research analysts have issued 1-year price targets for FibroGen's shares. Their FGEN share price targets range from $2.00 to $32.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,353.0% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.
How have FGEN shares performed in 2024?: FibroGen's stock was trading at $0.8863 at the beginning of 2024. Since then, FGEN stock has increased by 32.0% and is now trading at $1.17.
View the best growth stocks for 2024 here.
Are investors shorting FibroGen?: FibroGen saw a drop in short interest in March. As of March 31st, there was short interest totaling 5,190,000 shares, a drop of 6.1% from the March 15th total of 5,530,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is currently 1.9 days. Currently, 5.7% of the shares of the company are sold short.
View FibroGen's Short Interest.
When is FibroGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our FGEN earnings forecast.

How were FibroGen's earnings last quarter?: FibroGen, Inc. (NASDAQ:FGEN) issued its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.15. The biopharmaceutical company had revenue of $27.14 million for the quarter, compared to analyst estimates of $40 million.
What other stocks do shareholders of FibroGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).
When did FibroGen IPO?: FibroGen (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
How do I buy shares of FibroGen?: Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FGEN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial